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SUPPORTING ONLINE MATERIAL 
Bacterial growth media and conditions. All bacterial strains were grown in Luria broth  
(10 g of tryptone, 5 g of yeast extract, 10 g NaCl per liter of distilled water) or in LB agar 
plates at 37°C. Antibiotics were used at the following concentrations (per ml): 200 µg 
streptomycin (Sm); 50 µg ampicillin (Ap); 50 µg kanamycin (Kn). In Fig. 4B, S8 and 
S10, B. subtilis was grown in LB medium or LB containing L- or D-amino acids (mM: 
0.01 Ile, 0.03 Leu, 0.02 Pro, 0.06 Phe, 0.04 Tyr, 0.04 Val) whereas in Fig. S7 LB media 
was supplemented with the following concentrations (mM) of L- or D-amino acids: 0.01 
Ile, 0.03 Leu, 0.02 Pro, 0.06 Phe, 0.22 Tyr, 0.04 Val. The growth curves in Fig. 2 and S10 
were obtained using a DU530 Spectrophotometer (Beckman Coulter, Fullerton, CA). 
Strains and plasmids. The strains and plasmids used in this study are listed in Table S4. 
All V. cholerae strains used in this study were derived from the sequenced El Tor clinical 
isolate N16961 (1). E. coli strains DH5α and DH5α λpir were used for DNA cloning. 
SM10 λpir was used to mobilize DNA into V. cholerae by conjugation (2). Standard 
allele exchange techniques using derivatives of pCVD442 (3) were used to construct V. 
cholerae deletion mutants. Derivatives of the suicide vector pGP704 were used to 
construct chromosomal bsrV::his fusions. 
Reagents. All D-amino acids, and ninhydrin, were obtained from Sigma Aldrich (St. 
Louis, MO). BocillinFL and BodipyFL-vancomycin were obtained from Invitrogen 
(Carlsbad, CA).  
Preparation of cell-free supernatants and assay for mrcA sphere formation. Wild-
type, mrcA, or bsrV strains were grown in LB media for 20 h with shaking. Cells were 
pelleted at 5000 rpm for 10 min and supernatants were passed through Millipore 
(Bedford, MA) Millex-GV 0.22 µm syringe driven filter units or, for larger samples, 
Corning (Corning, NY) 1L Bottle Top 0.22 µm filters.  
 To test whether cell-free supernatants could induce sphere formation in mrcA V. 
cholerae, exponentially growing (~OD600nm 0.2) rod-shaped mrcA cells were 
centrifuged at 6000 rpm for 2 min, supernatant aspirated, and cells resuspended in media 
consisting of a 1:1 or 1:2 ratio of LB medium to cell-free supernatant.The cells were 
grown for 5, 15, or 40 min and imaged using phase-contrast microscopy. After addition 
of stationary phase supernatants to the mrcA mutant, spherical cells were seen within 5 
min and, as shown in Fig. 1B, by 15min  ~50% of cells were spherical. These changes are 
not likely to be accounted for by cell growth alone, since the generation time of V. 
cholerae is ~17 min under these conditions. In Fig. 1C, exponentially growing 
(~OD600nm 0.2) rod-shaped mrcA cells were imaged 45 min after the addition of 1.0 
mM L-Met or D-Met. Titration experiments revealed that the minimum concentration of 
D-Met required to induce sphere formation in the mrcA mutant was 0.5 mM.  
 mrcA (vc2635) encodes a V. cholerae homologue of E. coli PBP1A (similarity, 
73% (BLAST P-value  = 4.0 x e-238). V. cholerae encodes another high molecular mass 
PBP (VC0602) that is an orthologue of E. coli PBP1B (similarity, 67%, BLAST P value 
= 5.5 x e-184).  In contrast to our observations with the mrcA mutant, addition of D-amino 
acids to a vc0602 V. cholerae mutant did not alter its shape. These observations suggest 
that PBP1A in V. cholerae may be the dominant synthetic PBP in V. cholerae; 
alternatively, these observations may suggest that D-amino acids primarily target PBP1B 
rather than PBP1A. Thus, in the absence of PBP1A, cells are particularly sensitive to D-
amino acids.   
 Fractionation and identification of D-amino acids.  Cell-free stationary phase 
supernatant (1 L) from V. cholerae was dried by rotovap.  The dried material was 
resuspended in 10 mL of water and loaded on a Sephadex G-10 size exclusion column 
(2.5 cm diameter, 44 cm height) on water. The most active fractions were found in 
elution volumes of 49 mL - 56 mL. These fractions were pooled, dried, resuspended in 2 
mL of water, and fractionated through another Sephadex G-10 column (1.5 cm diameter, 
42 cm height). The most active fractions were found in elution volumes of 32 - 34 mL 
and analyzed by Nuclear Magnetic Resonance (NMR), Liquid Chromatography and Mass 
Spectrometry (LC/MS), and chemical derivatization. Based on 1H and gCOSY (gradient 
correlation spectroscopy) NMR (Varian 600 MHz NMR spectrometer) and LC/MS 
analysis, the major components of the active fraction turned out to be valine, leucine, 
isoleucine, and methionine. In order to determine the absolute configuration of the amino 
acids, the fraction was derivatized with L-FDAA (N-(2,4-dinitro-5-fluoro-phenyl)-L-
alanineamide)(4, 5). The fraction (1 mg) was dried and dissolved in 1N NaHCO3 (100 
L). 10 mg/mL of L-FDAA solution was prepared in acetone and 50 L of the solution 
was added to the fraction in 1N NaHCO3. The reaction mixture was incubated at 80oC for 
3 min and 50 L of 2N HCl was added to quench the reaction. 50% aqueous CH3CN 
(300 L), which dissolves FDAA derivatives, was added to the solution. The derivatives 
were analyzed by LC/MS using a gradient solvent system from 20% to 100% CH3CN 
with 0.1% formic acid over 40 min (Agilent 1200 Series HPLC/ 6130 Series MS, 
Phenomenex Luna C18)(4.6 mm  100 mm, 5m). The retention times of L-FDAA-amino 
acids were compared with L-FDAA-authentic standard amino acids. 
Amino acid quantification in supernatants. Standard solutions of all 19 chiral amino 
acids were prepared at various concentrations (0.001 – 0.2 mM). These solutions were 
analyzed by LC/MS with a gradient solvent system from 0% to 100% CH3CN with 0.1% 
formic acid over 20 min (Thermo Scientific Hypercarb 4.6 mm  100 mm, 5 m) to 
obtain calibration curves of each amino acid concentration by ion count integration. The 
supernatants were analyzed by LC/MS in the same manner to measure the total 
concentrations of all 19 chiral amino acids. 1 mL of supernatants were dried, derivatized 
with L-FDAA, and analyzed by LC/MS to determine the L and D ratios of the amino 
acids as described above. Based on the total concentrations and L/D ratios of the amino 
acids, D-amino acid concentrations were calculated. 
 Supernatants derived from cultures grown in LB were used for amino acid 
quantification. LB contains ~1.0 mM L-Met, suggesting  that there is sufficeint L-Met in 
the media to yield the levels of D-Met detected in Table S2. It is not known whether there 
are sufficient quantities of L-Met in the host environment for V. cholerae to generate mM 
levels of D-Met.  
Quantification of total murein. Wild-type, bsrV or bsrV supplemented with 0.5 mM D-
Met and 0.5 mM D-Leu were grown overnight for stationary phase samples. Wild-type 
and bsrV were grown to OD600 nm 0.4 for exponential samples. Cells were resuspended 
in 1 volume of PBS and dropped into 1 volume of boiling 10% SDS and vigorously 
stirred for 4 h and then stirred overnight at 37ºC.  The insoluble fraction (peptidoglycan) 
was recovered by centrifugation at 80,000 rpm x 15 min at 30ºC (TLA110 Beckman 
rotor; OptimaTM Max ultracentrifuge Beckman), and boiled again in 1% SDS for 2 h.  
Samples were then washed four times with H2O. DAP quantification was adapted from a 
previous report (6). Samples were hydrolyzed overnight in 6N HCl at 100°C in 1mL 
capacity-crystal ampoules (Wheaton).  Samples were dried and resuspended in water and 
mixed in a 1:1:1 ratio with pure acetic acid and ninhydrin reagent (250 mg ninhydrin, 4 
mL phosphoric acid 0.6 M, and 6 mL pure acetic acid).  Samples were measured at 
OD434 nm and the amounts of DAP were calculated based on a standard curve.  Total 
murein per cell of various samples were calculated based on colony forming units. Fig. 
3A displays the average ± standard deviations from three experiments.   
HPLC/MS analysis of PG. 5 L of wild-type V. cholerae or E. coli were grown in the 
presence or absence of 0.5 mM D-Met for 2.5 h to an OD600 nm 0.5 for exponential 
samples (also 20 mM D-Met for E. coli). 1 L of wild-type or bsrV V. cholerae was grown 
for 16 h for stationary samples. In the case of B. subtilis, 50 mL of culture were grown in 
the presence or absence of 0.5 mM or 5.0 mM D-Tyr for 2.5h to an OD600 nm 0.5. To 
extract the peptidoglycan, cells were pelleted, resuspended into a small volume of 
medium and slowly dropped into an equal volume of boiling 10% (w/v) SDS. The 
insoluble fraction (peptidoglycan) was recovered by centrifugation as described above, 
and further processed for HPLC analysis as previously described (7) on a Hypersil 
ODS18 reverse-phase column (250 mm by 4 mm; 3-mm particle size; (Teknochroma, 
Spain).  An Autoflex matrix-assisted laser desorption/ionization-time of flight (MALDI-
TOF) mass spectrometer (Bruckner Daltonics) in the positive ion mode was used to 
identify D-Tyr-containing muropeptides in muramidase treated PG isolated from B. 
subtilis.  
Low salt survival. Wild-type or bsrV mutant strains were grown for 20 h to reach 
stationary phase.  Cells were then pelleted at low speed and washed with 150 mM NaCl 
once before being resuspended in 150, 50, 5, or 0 mM NaCl. Cells were incubated in 
these conditions for 10 min at room temperature and viability was determined by plating 
on LB agar plates. In Fig. 3B, V. cholerae and to a greater extent V. cholera bsrV cells 
lysed upon exposure to low salt.  This was apparent by an immediate decrease in optical 
density after incubation in low salt.     
Bocillin-FL competition with D or L-Met. Cell membranes from wild-type V. cholerae 
were prepared as described (8). 0.3 g of the membrane preparation was incubated with 
0, 1, 10, or 100 mM D or L-Met for 30 min before adding Bocillin-FL to a final 
concentration of 50 µM.  Samples were incubated for 15 min at 37ºC (protected from the 
light) and run on an SDS PAGE gel.  Bocillin-FL staining was visualized on a Fujifilm 
FLA-5100 scanner.   
Van-BDP labeling of B. subtilis. BodipyFL vancomycin (Van-BDP) is a fluorescent 
derivative of vancomycin that is thought to label sites of nascent PG synthesis.   For Fig. 
4B, wild-type B. subtilis was maintained in exponential growth (OD600nm 0.1- 0.5) in 
LB media or LB containing L- or D-amino acids (mM: 0.01 Ile, 0.03 Leu, 0.02 Pro, 0.06 
Phe, 0.04 Tyr, 0.04 Val).  At 30 min, cells were washed and stained with 0.8 µg/mL of a 
1:1 mixture of vancomycin:van-BDP as described (9, 10). For Fig. S7, wild-type B. 
subtilis was maintained in exponential growth (OD600nm 0.1- 0.5) with an 
approximately 5-fold higher concentration of L- or D-Tyr (mM: 0.01 Ile, 0.03 Leu, 0.02 
Pro, 0.06 Phe, 0.22 Tyr, 0.04 Val). Cells were stained and imaged at 0.5, 2, 4, and 6 h.   
 The pattern of staining in exponentially growing  B. subtilis that we observed in 
Fig. 4b, predominantly septal and lateral wall staining, is consistent with previous reports 
(10). The infrequent staining detected at the cell poles is nonetheless expected for a small 
percentage of cells that have recently divided because division sites that create the new 
cell pole are areas of active PG synthesis.  
Microscopy.  For light microscopy imaging, V. cholerae and B. subtilis strains were 
placed on a microscope slide that was layered with a pad of 1% agarose made with M9 
medium. Samples were observed at room temperature (~ 22°C) on a Zeiss Axioplan 2 
microscope through a 100X phase contrast objective using a Hamamatsu Orca-ER LCD 
camera. Images were taken and processed with Metamorph software (Molecular Devices, 
PA). Average van-BDP intensity per cell was calculated using region measurement tools 
in Metamorph software. 
BsrV localization.  Wild-type V. cholerae N16961 and an isogenic derivative (N16961 
bsrV::pGP704-bsrVHis) that expresses a C-terminal His-tagged BsrV fusion protein were 
used to determine BsrV localization. An established protocol to release periplasmic 
contents using polymyxin B (616 µg/ml) was followed (11). The localization of the 
BsrV-His fusion protein was detected in Western blots with -6His antiserum (Genetex, 
Inc.).  Rabbit antisera raised against DegP, a periplasmic protein, and ribosomal protein 
S2, a cytoplasmic protein, were used as standards and generously provided by J. 
Beckwith and C. Squires respectively. 
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 Supplemental Legends 
 
Table S1. Differences in composition and structure of stationary and exponential phase 
PG from wild-type or bsrV V. cholerae. Monomer, dimer, and trimer represent 
muropeptide units, Anhydro: Anhydro-muropeptide, DAP-DAP: muropeptides 
crosslinked at two DAP units, Pentapeptide: full-length peptide chains.  Cross-linkage 
refers to cross-linking of peptide chains, whereas chain length refers to the average length 
of the glycan chains. 
 
Table S2. Release of D-amino acids in various bacteria (mM). D-amino acids detected at 
less than 0.005 mM are not displayed. 
 
Table S3. Putative amino acid racemase-encoding loci in various bacteria. Genes were 
included in this table based on their current annotations and/or their similarity to 
annotated amino acid racemases. 
 
Table S4. Strains and plasmids used in this study. 
 
Figure S1.  Ratio of L- and D-amino acids in stationary phase supernatant of wild-type 
V. cholerae. (A) The extracted LC/MS ion traces of the L-FDAA (N-(2, 4-dinitro-5-
fluoro-phenyl)-L-alanineamide) products of Met, Leu, Ile, and Val. (B) Calculated 
D/(D+L) ratios for each amino acid.  The products of Leu and Ile with identical mass 
were differentiated by comparing the retention times of the FDAA products derived from 
standards of Leu and Ile.   
 
Figure S2. Subcellular localization of BsrV-His in V. cholerae. Immunodetection of 
BsrV-His (46 KDa), DegP (48 KDa) and ribosomal protein S2 (27 KDa) in the 
supernatant (S), periplasm (P), membrane (M) and cytosol (C) fractions from V. cholerae 
wild-type (Wild-type) and a derivative strain expressing a C-terminal His-tagged BsrV 
fusion protein (Wild-type bsrV-his).  
 
Figure S3. The morphology of wild-type V. cholerae after addition of D-Met.  Cells were 
imaged 45 minutes after addition of 1 mM L- or D-Met. Bar size = 2 µm. 
 
Figure S4. Complete HPLC profiles of muramidase digested PG from V. cholerae and E. 
coli showing D-Met incorporation. PG isolated from (A) exponential (exp) or (B) 
stationary (stat) phase wild-type V. cholerae in unsupplemented LB. (C) Profiles 
comparing exponentially grown wild-type E. coli cells in (I) unsupplemented LB, (II) LB 
supplemented with 20 mM D-Met or (III) exponential wild-type V. cholerae grown in LB 
supplemented with 0.5 mM D-Met.  Note that the D-Met containing muropeptides in PG 
from E. coli and V. cholerae are identical. (D) E. coli grown in LB supplemented with 0.5 
mM D-Met.  
 
Figure S5. Addition of 2 mM D-Ala induces rod-shaped mrcA cells to become spherical.  
Images were acquired 45 minutes after addition of D-Ala. Bar size = 2 µm. 
 Figure S6. D-Met prevents the binding of a fluorescent penicillin derivative, BocillinFL, 
to several V. cholerae cell envelope-associated PBPs.  Membrane fractions were 
incubated with Penicillin G, or L- or D-Met at the indicated concentrations (mM) before 
labeling with 50 µM BocillinFL. Arrowheads indicate PBPs where D-Met has interfered 
with BocillinFL binding. 
 
Figure S7. Morphology of exponentially growing B. subtilis in LB supplemented with a 
mixture of L- or D-amino acids (mM: 0.01 Ile, 0.03 Leu, 0.02 Pro, 0.06 Phe, 0.22 Tyr, 
0.04 Val). At each time point, cells were stained with 0.8 µg/mL of a 1:1 mixture of 
vancomycin:van-BDP. Schematics of representative staining patterns are depicted. Bar 
size = 2 µm. 
 
Figure S8. Quantification of Van-BDP staining of exponential phase B. subtilis 
supplemented with a mixture of physiologic D-(or the corresponding L-) amino acids or 
unsupplemented exponential or stationary phase B. subtilis (N>200 cells measured per 
sample). 
 
Figure S9. Complete HPLC profiles of muramidase digested PG from B. subtilis 
showing D-Tyr incorporation. PG isolated from exponential wild-type B. subtilis in 
unsupplemented LB (A, B) or LB containing 0.5 mM D-Tyr (C, D). 204 nm absorbance 
(A,C) was used to detect all PG products, whereas 280 nm absorbance (B, D) detects 
primarily aromatic products. MALDI-TOF was used to identify D-Tyr containing peaks. 
M-Tyr: amidated monomer disaccharide pentapeptide, D-Tyr: di-amidated dimer 
disaccharide pentapetide-tetrapeptide. 
 
Figure S10. Growth of B. subtilis in LB ± a mixture of L- or D- amino acids (mM: 0.01 
Ile, 0.03 Leu, 0.02 Pro, 0.06 Phe, 0.04 Tyr, 0.04 Val). 
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Trimers
Lipoprotein
Anhydro
DAP-DAP
Pentapeptide
Cross-linkage
Chain Length
Wild type bsrV
Table S1. Differences in composition and structure of 
stationary and exponential phase PG from wild-type 
or bsrV V. cholerae.
63.3 ± 2.8
34 ± 2.3
2.7 ± 0.4
4.6 ± 0.5
10.2 ± 0.8
8.4 ± 0.3
1.0 ± 0.3
39.4 ± 3.2
10 ± 0.8
62.5 ± 2.1
5.1 ± 0.3
3.8 ± 0.1
33.7 ± 2.1
12.3 ± 0.3
7.4 ± 0.1
0.5 ± 0.3
41.2 ± 2.1
8.1 ± 0.3
71.0 ± 1.6
27.7 ± 1.5
1.3 ± 0.2
1.9 ± 0.5
8.0 ± 0.7
2.0 ± 0.6
0.7 ± 0.3
29.9 ± 0.2
12.5 ± 0.7
72.7 ± 1.4
1.2 ± 0.2
1.1 ± 0.2
26.3 ± 1.6
7.4 ± 0.4
1.1 ± 0.3
0.5 ± 0.2
28.4 ± 0.6
13.5 ± 0.4
Wild type bsrV
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D-Ala 0.00 - - - 0.87 - 0.01 0.01 - 1.52 - 4.00 2.40 1.05 0.61
D-Ile 0.03 - 0.02 - - 0.01 0.01 - - 0.03 0.01 0.03 - - -
D-Leu 0.29 0.51 0.76 0.03 0.01 0.02 0.03 - - 0.05 0.03 0.11 0.02 0.09 -
D-Met 0.50 0.35 0.28 0.01 - 0.01 0.01 - - - - 0.01 - - -
D-Phe 0.01 - - - 0.05 0.01 - - - - 0.06 0.04 0.01 0.07 -
D-Pro - - - - - - 0.04 - - 0.01 0.02 0.02 - 0.02 0.01
D-Thr - - - - - - - - - - - 0.06 - 0.14 -
D-Trp - - - - - - - - - - - 0.01 - - -
D-Tyr 0.00 - 0.00 0.01 0.00 - 0.01 - - 0.01 0.04 - 0.01 0.01 -
D-Val 0.17 - - - - 0.02 0.02 0.20 - - 0.04 0.05 0.07 0.04 -
D-Total 0.99 0.86 1.06 0.06 0.94 0.07 0.12 0.21 0.00 1.62 0.19 4.33 2.51 1.42 0.61
(-) indicates that D-aa was not detected
 
 
    
 
 
 
   
 
 
 
 
 
 
 
 
 
*    Putative amino acid racemases from the sequenced and annotated strain AU1054 and not from J2315 used in this 
study 
**  Formerly Nocardia corallina 
 
 
 
 
 
 
 
 
 
Table S3. Putative amino acid racemase-encoding loci in various bacteria. 
STRAIN LOCI ENCODING PUTATIVE AMINO ACID RACEMASES TOTAL 
Vibrio cholerae N16961 VC0372; VC1312 (BsrV); VC0461; VC0158 4 
Aeromonas hydrophila ATCC7966 AHA_1015; AHA_2536; AHA_2607; AHA_3664; AHA_0075; AHA_3590 6 
Bacteroides fragilis YCH46 BF0892; BF2949; BF0501 3 
Bacillus subtilis 168 BSU04660; BSU17640; BSU15380; BSU28390; BSU26810; BSU34430 6 
Burkholderia cenocepacia  AU 1054* 
Bcen_4288; Bcen_6038;  Bcen_5881; Bcen_2130; Bcen_4325; 
Bcen_4337; Bcen_4007; Bcen_4226; Bcen_6113; Bcen_5934; 
Bcen_6407 
11 
Caulobacter crescentus CB15 CC1661; CC3745; CC3703; CC2033; CC3278 5 
Deinococcus radiodurans DR1086; DR1586; DR1368 3 
Escherichia coli K12 MG1655 B4053; B1190; B3381; B2951; B2247; B3967; B2840 7 
Rhodococcus rhodochrous B-276 ** GENOME NOT SEQUENCED ND 
Pseudomonas aeruginosa PA01 PA4930; PA5302; PA0394; PA5326; PA4662; PA1255; PA1268 6 
Staphylococcus  aureus MW2 MW1994; MW1287; MW1071; MW2104; MW1033 5 
Streptomyces lividans JI66 GENOME NOT SEQUENCED ND 
Thermus thermophilus HB27 TTC1944; TTC1280; TTC0519 3 
Vibrio parahaemolyticus RIMD 2210633 VP2734; VPA1001; VP2848; VP2616; VP2936; VPA6013 6 
Yersinia enterocolitica, subsp. enterocolitica 8081 YE3848; YE2280; YE1043; YE3433; YE3103; YE0140; YE1289 4 
 
 
 
Table S4. Strains and plasmids 
Strains Relevant Genotype or Description Reference or source 
V. cholerae    
MKW618 N16961, wild-type El Tor Clinical Isolate (SmR) (1) 
MKW619 N16961 ∆mrcA::kan This study 
MKW620 N16961 ∆bsrV This study 
E.coli   
SM10 pir thi thr leu tonA lacY supE recA::RP-4-2-Tc::Mu(lpir) pro endA  hsdA hsdR supF (2) 
DH5 Cloning strain  
DH5 pir Cloning strain; pir R6K  
MG1655 K-12 F- lambda- ilvG- rfb-50 rph-1 E. coli 
Genetic Stock  
   
A. hydrophila A. hydrophila clinical isolate P. Watnick 
Y. enterocolitica  Y. enterocolitica  wild-type strain  JB580c (12) 
P. aeruginosa P. aeruginosa  wild-type strain  PA01 (13) 
S. aureus S. aureus wild-type strain  MT8 (14) 
B. subtilis B. subtilis wild-type strain  PY79 (15) 
B. fragilis B. fragilis wild-type strain YCH46 (16) 
C. crescentus C. crescentus wild-type strain CB15N (17) 
V. parahaemolyticus V. parahaemolyticus wild-type strain VP47 (18) 
B. cenocepacia B. cenocepacia  wild-type strain  J2315 (19) 
D. radiodurans D. radiodurans wild-type strain  R1 (20) 
R. rhodochrous R. rhodochrous wild-type strain B276 (21) 
S. lividans S. lividans wild-type strain  JI66 (22) 
T. thermophilus T. thermophilus wild-type strain  HB27 (23) 
Plasmid Description and Construction Reference or 
source 
pCVD442 Suicide vector containing the counter-selectable marker sacB (ApR) (3) 
pKD4 KnR containing plasmid (24) 
pGP704 Suicide vector bearing oriR6K. Integrative through homologous 
recombination in strains lacking the pir gene (ApR). 
(2) 
pCVD442∆mrcA::kan An allele exchange vector used to generate mrcA::kan (mrcA) in V. cholerae.  
The regions upstream and downstream of mrcA were amplified with the forward 
primer 5’-GCTCTAGACCACCAACATCCAGTCTGG-3’ (prPBP1a1) and 
reverse primer 5’-CAGGATCCGAATCCCTGTTTAGTTGAGG-3’ (prPBP1a2) 
and forward primer 5’-GCGAATTCCGACCAGCTCTGGTGAAG-3’ 
(prPBP1a3) and reverse primer 5’-CATCTAGACGGTGGAAGAGACGGCAC-
3’ (prPBP1a4), respectively and digested with XbaI/BamHI and EcoRI/XbaI 
respectively.  KnR was amplified from pKD4 using the primers 5’-
CGGAATTCCCCGCGCTGGAGGATCATC-3’ (Kan3) and reverse primer 5’-
CGGGATCCAGCTACTGGGCTATCTGGAC-3’ (Kan5) and digested with 
BamHI/EcoRI.  Products were ligated into the XbaI site of pCVD442 
This study 
pCVD442∆bsrV An allele exchange vector used to generate ∆bsrV in V. cholerae.  The regions 
upstream and downstream of bsrV were amplified with the forward primer 5’-
CACCTCTAGACCAAGCGATGGCAGCCAA-3’ (Dvc1312 A) and reverse 
primer 5’-GGTCGCTAGCCTCCAAGTCGCAAGAAGA-3’ (Dvc1312B) and 
forward primer 5’- GGTGGCTAGCGTGAAATAAGCTATACCC-3’ 
(Dvc1312C) and reverse primer 5’-
CACCTCTAGACCAAGAATAGCCAACGCA-3’ (Dvc1312D), respectively.  
These products were digested with NheI and ligated to each other.  The products 
were cut with XbaI and ligated into this site in pCVD442 
This study 
pGP704bsrV-His pGP704 derivative plasmid which contains a fragment of the bsrV gene 
amplified with the forward primer: 5’-
AAATCTAGACACACTGCATGTTGCGAACTCTTACACCGCG-3’ 
(CtbsrVFwXba) and the reverse primer 5’-
AAGAATTCTTAGTGATGATGATGATGATGGCCGCTGCTTT 
TCACGTAGAAACGTGGGTTACTGGTTCCCC-3’ (CtbsrVHisEcorevst)). The 
product was digested with XbaI/EcoRI and ligated into the same restriction sites 
of the pGP704 vector. The homologous integration of the vector generates a 
translational C-term fusion of BsrV with a 6-His peptide tag. 
This study 
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M4: GlcNAc-MurNAc-L-Ala-D-Glu-DAP-D-Ala
M4-Gly: GlcNAc-MurNAc-L-Ala-D-Glu-DAP-D-Ala-Gly
M2: GlcNAc-MurNAc-L-Ala-D-Glu
M5: GlcNAc-MurNAc-L-Ala-D-Glu-DAP-D-Ala-D-Ala
M3-Lp: GlcNAc-MurNAc-L-Ala-D-Glu-DAP
D-3(LD)4: M3-M4 (crosslinked at DAP-DAP)
D-43: M4-M3 (crosslinked at D-Ala-DAP)
D-44: M4-M4 (crosslinked at D-Ala-DAP)
M-3A: GlcNAc-(1-6anhdro)MurNAc-L-Ala-D-Glu-DAP
M-4A: GlcNAc-(1-6anhdro)MurNAc-L-Ala-D-Glu-DAP-D-Ala
D-45: M4-M5 (crosslinked at D-Ala-DAP)
D-43-Lp: M4-M3-Lp (crosslinked at D-Ala-DAP)
T-444: M4-M4-M4 (crosslinked at D-Ala-DAP and D-Ala-DAP)
D-3(LD)4A: M-3A-M4 (crosslinked at D-Ala-DAP)
D-44A: M-4A-M4 (crosslinked at D-Ala-DAP)
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